Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
I was diagnosed with multiple myeloma in early 1994. I underwent VAD induction therapy and an autologous stem cell transplant in 12/95.
I developed chronic atrial fibrillation (Afib) in December of 2010 and chemotherapy-induced cardiomyopathy. The issue of cardiotoxic chemotherapy regimens is near and dear to my heart.
First and foremost, conventional oncology doesn’t really know what the risk of late stage heart failure is. Secondly, that’s what people say until the problem happens to them. Risk is always small until it happens to you…
Further, I’m not saying that cancer patients should “stop using cancer drugs that save lives…” Not at all. I am saying two things.
How many other cancer survivors who have undergone cardio-toxic chemo who’s hearts have been damaged yet are not yet exhibiting signs of heart failure!?!? How many cancer survivors are walking around with:
The fact that FDA warnings are issued years after formally approving the drug tells me that evidence of heart damage often occurs long after the patient completes his/her active therapy.
If you are currently undergoing one of the many known cardio-toxic chemotherapy drugs, I encourage you to also undergo evidence-based, non-toxic, heart-healthy complementary therapies such as nutrition, moderate exercise, supplementation, and lifestyle therapies.
To learn more about heart healthy complementary therapies, scroll down the page, post a question or comment and I will reply to you ASAP.
“The US Food and Drug Administration (FDA) has issued postmarket cardiac safety warnings for about 1 in 4 cancer therapies, according to a research letter published September 30 in JAMA Oncology…
The US Food and Drug Administration (FDA) has issued postmarket cardiac safety warnings for about 1 in 4 cancer therapies, according to a research letter published September 30 in JAMA Oncology.
These cardiotoxic risk communications typically were issued just over 4.5 years after a drug’s approval — 40% longer than it took to issue noncardiac warnings.
However, lead author Daniel Addison, MD, explained that the likelihood of having a major cardiac event related to a cancer drug appears to be quite small.
“I don’t think people should stop using cancer drugs that are saving lives,” said Addison, co-director of the Cardio-Oncology Program at the Ohio State University Comprehensive Cancer Center–James Cancer Hospital and Solove Research Institute, Columbus, Ohio. Rather, clinicians treating cancer patients should use a lower threshold for initiating a cardiovascular workup “if a patient is showing signs or symptoms of a potential heart issue.”
According to the researchers, cardiovascular events have become increasingly common with the use of cancer therapies, but “the prevalence and factors associated with these warnings are unknown.”
The authors found that of 125 FDA-approved cancer treatments, cardiovascular disease warning were issued for 32 (25.6%). Multiple warnings were issued for two dozen therapies (21.6%). Warnings were issued for more than 40% of the immune and targeted therapies — a total of 15 drugs.
were the most common reasons for a cardiac safety communication…
Addison noted that the average timing of cardiac safety communications masks wide variations by event type. Alerts regarding heart failure or hypertension, for example, emerged around 1200 days after a drug approval, but it took more than 2000 days for alerts about arrhythmias to be issued.
The authors said that the “delayed recognition is concerning, particularly given the rapid emergence of many targeted and immune-based cancer therapies, and the potentially devastating consequences of cardiotoxic events…”
“In a lot of cases, these newer drugs are really changing how we treat cancer patients,” said Eiman Jahangir, MD, MPH. “And typically, the benefit of curing a cancer outweighs the risk of a potential cardiac outcome, but as clinicians, we also need to know what [risks] to look for. If we know [about the risk for cardiac events], then we’re more likely to pick them up when a patient presents with symptoms.”